Elisabeth Parker appointed as Business development expert in Hamlet BioPharma and joins the team on March 3rd

Hamlet BioPharma has appointed Elisabeth Parker, PhD to strengthen the business development expertise in the company. Dr. Parker has 25 years’ experience of R&D, partnering and commercialization of therapeutics, diagnostics and enabling technologies. Dr. Parker leaves her current position as Senior Investment Advisor Healthcare and Life Sciences at Business Sweden to take up the 80% position with Hamlet BioPharma. Elisabeth Parker will leave the board of Hamlet Biopharma at the upcoming extraordinary general meeting as she now takes on a management role in the company.

Dr Parker received a PhD in 1998 from the Medical Faculty, Lund University, Sweden. More recently, she has served as Director of Business Development at the Immunotherapy company Macrophage Pharma, Business development executive at the development and commercialization arm of Cancer Research UK (CRUK) and Non-Executive Board Director of Azeria Ltd and Arquer diagnostics Ltd.

This recruitment strengthens the business development process of Hamlet BioPharma and adds high profile pharma competence and active international networks, says Catharina Svanborg, CEO of Hamlet BioPharma.
For more information, please contact:

Catharina Svanborg, CEO.

Phone: +46 709 42 65 49

E-mail: catharina.svanborg@hamletbiopharma.com